Supplementary Table 1 from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Yan Feng,Ye Wang,Zuoyun Wang,Zhaoyuan Fang,Fei Li,Yijun Gao,Hongyan Liu,Tian Xiao,Fuming Li,Yang Zhou,Qiwei Zhai,Xiaolong Liu,Yihua Sun,Nabeel Bardeesy,Kwok-kin Wong,Haiquan Chen,Zhi-qi Xiong,Hongbin Ji

DOI: https://doi.org/10.1158/0008-5472.22395500.v1

2023-01-01

Abstract:PDF file - 139K, The list of primers used in this study

What problem does this paper attempt to address?

Supplementary Methods from the CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Yan Feng,Ye Wang,Zuoyun Wang,Zhaoyuan Fang,Fei Li,Yijun Gao,Hongyan Liu,Tian Xiao,Fuming Li,Yang Zhou,Qiwei Zhai,Xiaolong Liu,Yihua Sun,Nabeel Bardeesy,Kwok-kin Wong,Haiquan Chen,Zhi-qi Xiong,Hongbin Ji

DOI: https://doi.org/10.1158/0008-5472.22395503

2023-01-01

Abstract:PDF file - 161K, Supplementary methods about plasmids and antibodies, immunofluorescence, soft agar assay and boyden chamber assay
Supplementary Figures 1-12 from the CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Yan Feng,Ye Wang,Zuoyun Wang,Zhaoyuan Fang,Fei Li,Yijun Gao,Hongyan Liu,Tian Xiao,Fuming Li,Yang Zhou,Qiwei Zhai,Xiaolong Liu,Yihua Sun,Nabeel Bardeesy,Kwok-kin Wong,Haiquan Chen,Zhi-qi Xiong,Hongbin Ji

DOI: https://doi.org/10.1158/0008-5472.22395509

2023-01-01

Abstract:PDF file - 307K, Supplementary Figure S1. Ectopic NEDD9 expression partially reverses the inhibitory function of LKB1 upon cell migration and invasion of human lung cancer cells. Supplementary Figure S2. shNedd9 inhibits lung cancer progression in de novo KrasG12D, Lkb1L/L mouse model. Supplementary Figure S3. NEDD9 promotes lung cancer progression in de novo KrasG12D mouse model. Supplementary Figure S4. LKB1 specifically regulates CRE-Luc activity. Supplementary Figure S5. shCRTC1 down-regulates NEDD9 mRNA expression. Supplementary Figure S6. Screening for the responsive element of CRTC1/CREB on NEDD9 promoter. Supplementary Figure S7. LKB1 regulates NEDD9 promoter activity through the non-classical CRE site. Supplementary Figure S8. Immunofluorescence assay showed that ectopic Flag-LKB1 expression promoted SIK2 translocation into nucleus in A549 cells. Supplementary Figure S9. Immunofluorescence assay showed that LKB1 knockdown promoted SIK2 translocation into cytoplasm while CRTC1 translocation into nucleus in CRL-5866 cells. Supplementary Figure S10. SIK2 knockdown up-regulates NEDD9 mRNA expression via promoting CRTC1 nuclear translocation. Supplementary Figure S11. Ectopic CRTC1 expression partially reverses the inhibitory function of LKB1 upon cell migration and invasion of human lung cancer cells. Supplementary Figure S12. NEDD9 immunostaining in human lung cancer specimens
Data from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Yan Feng,Ye Wang,Zuoyun Wang,Zhaoyuan Fang,Fei Li,Yijun Gao,Hongyan Liu,Tian Xiao,Fuming Li,Yang Zhou,Qiwei Zhai,Xiaolong Liu,Yihua Sun,Nabeel Bardeesy,Kwok-kin Wong,Haiquan Chen,Zhi-qi Xiong,Hongbin Ji

DOI: https://doi.org/10.1158/0008-5472.c.6504317

2023-01-01

Abstract:AbstractSomatic mutation of the tumor suppressor gene LKB1 occurs frequently in lung cancer where it causes tumor progression and metastasis, but the underlying mechanisms remain mainly unknown. Here, we show that the oncogene NEDD9 is an important downstream mediator of lung cancer progression evoked by LKB1 loss. In de novo mouse models, RNAi-mediated silencing of Nedd9 inhibited lung tumor progression, whereas ectopic NEDD9 expression accelerated this process. Mechanistically, LKB1 negatively regulated NEDD9 transcription by promoting cytosolic translocation of CRTC1 from the nucleus. Notably, ectopic expression of either NEDD9 or CRTC1 partially reversed the inhibitory function of LKB1 on metastasis of lung cancer cells. In clinical specimens, elevated expression of NEDD9 was associated with malignant progression and metastasis. Collectively, our results decipher the mechanism through which LKB1 deficiency promotes lung cancer progression and metastasis, and provide a mechanistic rationale for therapeutic attack of these processes. Cancer Res; 72(24); 6502–11. ©2012 AACR.
Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528425

2023-01-01

Abstract:PDF file, 64K, Non-small cell lung cancer cell lines.
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai Tran,Robert J.G. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun K. Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22446704

2023-01-01

Abstract:PDF file - 66K, CDH1 probes vary in their accuracy and dynamic range
The Crtc1-Nedd9 Signaling Axis Mediates Lung Cancer Progression Caused By Lkb1 Loss

Yan Feng,Ye Wang,Zuoyun Wang,Zhaoyuan Fang,Fei Li,Yijun Gao,Hongyan Liu,Tian Xiao,Fuming Li,Yang Zhou,Qiwei Zhai,Xiaolong Liu,Yihua Sun,Nabeel Bardeesy,Kwok-kin Wong,Haiquan Chen,Zhi-qi Xiong,Hongbin Ji

DOI: https://doi.org/10.1158/0008-5472.CAN-12-1909

IF: 11.2

2012-01-01

Cancer Research

Abstract:Somatic mutation of the tumor suppressor gene LKB1 occurs frequently in lung cancer where it causes tumor progression and metastasis, but the underlying mechanisms remain mainly unknown. Here, we show that the oncogene NEDD9 is an important downstream mediator of lung cancer progression evoked by LKB1 loss. In de novo mouse models, RNAi-mediated silencing of Nedd9 inhibited lung tumor progression, whereas ectopic NEDD9 expression accelerated this process. Mechanistically, LKB1 negatively regulated NEDD9 transcription by promoting cytosolic translocation of CRTC1 from the nucleus. Notably, ectopic expression of either NEDD9 or CRTC1 partially reversed the inhibitory function of LKB1 on metastasis of lung cancer cells. In clinical specimens, elevated expression of NEDD9 was associated with malignant progression and metastasis. Collectively, our results decipher the mechanism through which LKB1 deficiency promotes lung cancer progression and metastasis, and provide a mechanistic rationale for therapeutic attack of these processes. Cancer Res; 72(24); 6502-11. (c) 2012 AACR.
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528419.v1

2023-01-01

Abstract:PDF file, 53K, mRNA transcripts significantly different between SCLC and NSCLC cell lines.
Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395236.v1

2023-01-01

Abstract:Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Table 1 from NCOA1 Directly Targets &Lt;i>m-Csf1 Expression to Promote Breast Cancer Metastasis

Qin Li,Yelin Wu,Michael J. Toneff,Dabing Li,Lei Lan,Xiuhua Gao,Fiona T. Bane,Jean C. Tien,Yan Xu,Feng Zhu,Yang Zhang,Sarah M. Theissen,Yang Li,Leonie S. Young,Jian‐Xin Xu

DOI: https://doi.org/10.1158/0008-5472.22399154.v1

2023-01-01

Abstract:PDF file - 93KB, PCR Primers and TaqMan qPCR Probes.
Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Tao Yu,Yingjun Zhao,Zhixiang Hu,Jing Li,Dandan Chu,Jiwei Zhang,Zhe Li,Bing Chen,Xiao Zhang,Hongyu Pan,Shengli Li,Hechun Lin,Lei Liu,Mingxia Yan,Xianghuo He,Ming Yao

DOI: https://doi.org/10.1158/0008-5472.22418429.v1

2023-01-01

Abstract:Several tables contain the nucleotide sequences, antibodies information, LncRNA expression profiles, LncRNA screening, the correlation between MetaLnc9 and clinicopathological features, the mass spectrometric analysis results, RNA-seq analysis, KEGG and GSEA analysis.
Supplementary Figure 5 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Matias Casás-Selves,Jihye Kim,Zhiyong Zhang,Barbara A. Helfrich,Dexiang Gao,Christopher C. Porter,Hannah A. Scarborough,Paul A. Bunn,Daniel C. Chan,Aik Choon Tan,James DeGregori

DOI: https://doi.org/10.1158/0008-5472.22391502.v1

2023-01-01

Abstract:PDF file - 222K, Demonstration that beta-catenin or TCF-4 knockdown results in enhanced sensitivity of NSCLC cells to gefitinib treatment, that beta-catenin or TCF-4 knockdowns reduce the expression of the corresponding protein, that there is minimal correlation between the expression of canonical Wnt target genes and gefitinib sensitivity for a panel of NSCLC cell lines, that there is no significant correlation of SLuGs with gefitinib induced genes, and that SLuGs are not enriched in lung cancer specific genes
Supplementary Table S2 from Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer

Linjie Zhao,Gaili Ji,Xiaobing Le,Chenlu Wang,Lian Xu,Min Feng,Yaguang Zhang,Huiliang Yang,Yu Xuan,Yanfei Yang,Lingzi Lei,Qilian Yang,Wayne Bond Lau,Bonnie Lau,Yi Chen,Xiangbing Deng,Shaohua Yao,Tao Yi,Xia Zhao,Yuquan Wei,Shengtao Zhou

DOI: https://doi.org/10.1158/0008-5472.22416774.v1

2023-01-01

Abstract:Primers for RT-PCR.
Suppl. Tables S1-S5 from RAD50 Expression is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer

Yifan Wang,Jayanthi Gudikote,Uma Giri,Jun Yan,Weiye Deng,Rui Ye,Jinyu Wen,Nan Li,Brian P. Hobbs,Jing Wang,Stephen G. Swisher,Junya Fujimoto,Ignacio I. Wistuba,Ritsuko Komaki,John V. Heymach,Steven H. Lin

DOI: https://doi.org/10.1158/1078-0432.22467236.v1

2023-01-01

Abstract:Supplementary Table S1. List of all primers and oligos used in this study. Supplementary Table S2. Subcellular staining locations of 12 candidate marker proteins in tumor microarray. Supplementary Table S3. Staining results for 17 candidate marker protein variables in the tumor microarray. Supplementary Table S4. Univariate and multivariate analyses of associations between clinical variables and RAD50 expression for OS, LRRFS, DMFS and DFS among 127 NSCLC patients. Supplementary Table S5. Univariate and multivariate analyses of associations between all the 17 markers and OS, LRRFS, DMFS and DFS among 127 NSCLC patients.
Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Ling Li,Wenhua Tang,Xiaoqing Wu,David Karnak,Xiaojie Meng,Rachel Thompson,Xinbao Hao,Yongmin Li,Xiaotan T. Qiao,Jiayuh Lin,James Fuchs,Diane M. Simeone,Zhi-Nan Chen,Theodore S. Lawrence,Liang Xu

DOI: https://doi.org/10.1158/1078-0432.22446368.v1

2023-01-01

Abstract:PDF file - 112K, The sequences of the oligonucleotide primers used for qPCR (related to the qRT-PCR section of Materials and Methods).
Supplementary Figure 5 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401678

2023-01-01

Abstract:PDF file - 570K, LCN2 promotes lung metastasis in balb/c nude mice.
Supplementary Table 7-10 from Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2

Qun Chen,Jinquan Cai,Qixue Wang,Yunfei Wang,Mingyang Liu,Jingxuan Yang,Junhu Zhou,Chunsheng Kang,Min Li,Chuanlu Jiang

DOI: https://doi.org/10.1158/1078-0432.22464858

2023-01-01

Abstract:Supplementary Table 7. Sequences of sgRNA and siRNA Supplementary Table 8. HOTAIR 5'mut and NEAT1 probe sequence Supplementary Table 9. PCR primer sequences Supplementary Table 10. Sequences of biotin probes
Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

Ling-Min Kong,Cheng-Gong Liao,Yang Zhang,Jing Xu,Yu Li,Wan Huang,Yi Zhang,Huijie Bian,Zhi-Nan Chen

DOI: https://doi.org/10.1158/0008-5472.22402862

2023-01-01

Abstract:PDF file - 75K, Oligonucleotide sequence of PCR primers and siRNA fragments.

Supplementary Table 1 from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by <i>LKB1</i> Loss

Supplementary Methods from the CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Supplementary Figures 1-12 from the CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Data from The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by <i>LKB1</i> Loss

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

The Crtc1-Nedd9 Signaling Axis Mediates Lung Cancer Progression Caused By Lkb1 Loss

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Table 1 from NCOA1 Directly Targets &Lt;i>m-Csf1</i> Expression to Promote Breast Cancer Metastasis

Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Supplementary Figure 5 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Supplementary Table S2 from Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer

Suppl. Tables S1-S5 from RAD50 Expression is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer

Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Figure 5 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Table 7-10 from Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2

Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis